Inventor · disambiguated record
Anthony E. Carpanzano
Also filed as: CARPANZANO ANTHONY · CARPANZANO ANTHONY E
11 granted patents·6 pending applications·370 citations·filing 1988–2022
89Inventor score
Files withENDO PHARMACEUTICALS INC5PURDUE PHARMA LP3BAICHWAL ANAND R2J RETTENMAIER & SOEHNE GMBH CO KG1JRS PHARMA GMBH & CO KG1
Top patents by PatentIndex Score
17 records- 0196US7384653B2Oral dosage form comprising a therapeutic agent and an adverse-effect agentPURDUE PHARMA LP·Filed 2004·Granted Jun 10, 2008·89 cites·39 claims
- 0295US4996047ASustained release drug-resin complexesRICHARDSON VICKS INC·Filed 1988·Granted Feb 26, 1991·264 cites·16 claims
- 0387US8394812B2Sustained release formulations of nalbuphineBAICHWAL ANAND R·Filed 2008·Granted Mar 12, 2013·9 cites·57 claims
- 0478US8771732B2Sustained release formulations of nalbuphineBAICHWAL ANAND R·Filed 2006·Granted Jul 8, 2014·3 cites·24 claims
- 0577USRE45822EOral dosage form comprising a therapeutic agent and an adverse-effect agentPURDUE PHARMA LP·Filed 2013·Granted Dec 22, 2015·2 cites·39 claims
- 0673US9351938B2Sustained release formulation of nalbuphineENDO PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·1 cites·24 claims
- 0772US8765175B2Sustained release formulation of nalbuphinePENWEST PHARMACEUTICALS CO·Filed 2013·Granted Jul 1, 2014·1 cites·37 claims
- 0870US9186330B2Sustained release formulation of nalbuphineENDO PHARMACEUTICALS INC·Filed 2014·Granted Nov 17, 2015·1 cites·37 claims
- 0967US10406106B2Sustained release formulations of nalbuphineENDO PHARMACEUTICALS INC·Filed 2018·Granted Sep 10, 2019·0 cites·21 claims
- 1063US10172798B2Sustained release formulation of nalbuphineENDO PHARMACEUTICALS INC·Filed 2017·Granted Jan 8, 2019·0 cites·24 claims
- 1158US2014199383A1Abuse resistant opioid containing transdermal systemsPURDUE PHARMA LP·Filed 2014·Application pending·0 cites
- 1257US2016263035A1Sustained release formulation of nalbuphineENDO PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1355US2023201124A1Lubricant for pharmaceuticals and nutraceuticalsJRS PHARMA GMBH & CO KG·Filed 2022·Application pending·0 cites
- 1450US2004241218A1Abuse resistant opioid containing transdermal systemsFiled 2002·Application pending·0 cites
- 1550US2003044458A1Oral dosage form comprising a therapeutic agent and an adverse-effect agentFiled 2002·Application pending·0 cites
- 1647US10166185B2Excipient and oral solid dosage forms for oily drugsJ RETTENMAIER & SOEHNE GMBH CO KG·Filed 2016·Granted Jan 1, 2019·0 cites·16 claims
- 1738US2015037424A1Sustained release oral solid preparationOTSUKA PHARMA CO LTD·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →